Gara Jalqabaatti › Luukemiya Mayiloodii Faasii Keessummaa › Texas
Qorannoo klinikaalii Luukemiya Mayiloodii Faasii Keessummaa Texas keessatti
Qorannoo 6 Luukemiya Mayiloodii Faasii Keessummaa f Texas keessatti hirmaatuu jiru.
Magaalota Texas keessatti
Takkalaa qorannoo (Ingiliffa)
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1051, Amarillo
- Ascentage Investigative Site #1036, Austin
- Ascentage Investigative Site #1501, Houston
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT06423911Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 15 hanga 80 · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT02727803A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
- Baylor Scott and White Research, Temple
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 20-Ado-2026 · NCT07091019A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- The University of Texas MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Elb-2026 · NCT05304377A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
- The University of Texas M.D. Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 12-Ama-2026 · NCT06163430Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.